IL121947A0 - Pharmaceutical compositions containing uracil derivatives - Google Patents

Pharmaceutical compositions containing uracil derivatives

Info

Publication number
IL121947A0
IL121947A0 IL12194797A IL12194797A IL121947A0 IL 121947 A0 IL121947 A0 IL 121947A0 IL 12194797 A IL12194797 A IL 12194797A IL 12194797 A IL12194797 A IL 12194797A IL 121947 A0 IL121947 A0 IL 121947A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
uracil derivatives
containing uracil
halo
Prior art date
Application number
IL12194797A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL121947(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL121947A0 publication Critical patent/IL121947A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Vibration Dampers (AREA)
  • Semiconductor Lasers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Springs (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Laminated Bodies (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Transformer Cooling (AREA)
  • Medicinal Preparation (AREA)
IL12194797A 1990-09-26 1997-10-10 Pharmaceutical compositions containing uracil derivatives IL121947A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909020930A GB9020930D0 (en) 1990-09-26 1990-09-26 Pharmaceutical combinations
IL9956291A IL99562A (en) 1990-09-26 1991-09-25 Pharmaceutical preparations containing an arachnoid history and their preparation

Publications (1)

Publication Number Publication Date
IL121947A0 true IL121947A0 (en) 1998-03-10

Family

ID=10682770

Family Applications (2)

Application Number Title Priority Date Filing Date
IL9956291A IL99562A (en) 1990-09-26 1991-09-25 Pharmaceutical preparations containing an arachnoid history and their preparation
IL12194797A IL121947A0 (en) 1990-09-26 1997-10-10 Pharmaceutical compositions containing uracil derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL9956291A IL99562A (en) 1990-09-26 1991-09-25 Pharmaceutical preparations containing an arachnoid history and their preparation

Country Status (30)

Country Link
US (5) US6268374B1 (xx)
EP (2) EP0985415A1 (xx)
JP (2) JP2682739B2 (xx)
KR (1) KR100222329B1 (xx)
AT (1) ATE190489T1 (xx)
BR (1) BR1100356A (xx)
CA (2) CA2092435C (xx)
CZ (4) CZ16196A3 (xx)
DE (1) DE69132052T2 (xx)
DK (1) DK0550580T3 (xx)
ES (1) ES2143465T3 (xx)
FI (1) FI112601B (xx)
GB (1) GB9020930D0 (xx)
GR (1) GR3033388T3 (xx)
HK (1) HK1004188A1 (xx)
HU (1) HU219589B (xx)
IE (1) IE20010101A1 (xx)
IL (2) IL99562A (xx)
MC (1) MC2307A1 (xx)
MY (1) MY128980A (xx)
NO (2) NO313175B1 (xx)
NZ (2) NZ250799A (xx)
PT (1) PT99041B (xx)
RU (1) RU2194511C2 (xx)
SG (1) SG47912A1 (xx)
SK (1) SK281894B6 (xx)
TW (1) TW271397B (xx)
UA (1) UA42679C2 (xx)
WO (1) WO1992004901A1 (xx)
ZA (1) ZA917667B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
HUT67392A (en) * 1991-05-15 1995-04-28 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
GB9322795D0 (en) * 1993-11-05 1993-12-22 Wellcome Found Novel compounds
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
US20080255168A1 (en) * 2004-12-03 2008-10-16 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
JP2008521930A (ja) * 2004-12-03 2008-06-26 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法
AU2012200856B2 (en) * 2004-12-03 2013-10-10 Adherex Technologies Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
BR112012008951A2 (pt) 2009-10-14 2019-09-24 Adherex Tech Inc tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd
US10556872B2 (en) 2017-03-17 2020-02-11 Hampton University Fatty acid synthase inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324126A (en) * 1963-08-07 1967-06-06 Univ Kansas State Production of 5-trifluoromethyluracil
US4124765A (en) 1975-05-13 1978-11-07 Ono Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
DE2522369A1 (de) 1975-05-21 1976-12-02 Ono Pharmaceutical Co 5-fluoruracilderivate und verfahren zu ihrer herstellung
DD122381A1 (xx) * 1975-10-03 1976-10-05
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
JPS6094971A (ja) * 1983-10-31 1985-05-28 Sagami Chem Res Center ５−ペルフルオロアルキルウラシル類の製造方法
US4719214A (en) 1985-07-25 1988-01-12 Southern Research Institute Carbocyclic analogues of thymine nucleosides
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US4874602A (en) 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
WO1989009213A1 (en) * 1988-03-31 1989-10-05 Mitsubishi Kasei Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
ATE154359T1 (de) * 1988-08-25 1997-06-15 Yoshitomi Pharmaceutical 2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
IE902574A1 (en) 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
ES2111569T3 (es) * 1990-07-19 1998-03-16 Wellcome Found Inactivadores de enzimas.
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
IE20010101A1 (en) 2002-03-20
CA2092435C (en) 2002-11-12
NZ250799A (en) 1995-11-27
DK0550580T3 (da) 2000-12-04
AU8540591A (en) 1992-04-15
DE69132052T2 (de) 2000-08-03
CA2092435A1 (en) 1992-03-27
CZ16196A3 (en) 1996-05-15
HU219589B (hu) 2001-05-28
EP0550580A1 (en) 1993-07-14
AU654505B2 (en) 1994-11-10
CZ16296A3 (en) 1996-05-15
NZ239927A (en) 1995-11-27
CA2390654A1 (en) 1992-04-02
US7119096B2 (en) 2006-10-10
US5817664A (en) 1998-10-06
NO931118D0 (no) 1993-03-25
NO980717L (no) 1993-03-25
BR1100356A (pt) 2003-02-25
GR3033388T3 (en) 2000-09-29
TW271397B (xx) 1996-03-01
CZ170995A3 (en) 1995-12-13
ZA917667B (en) 1993-03-25
RU2194511C2 (ru) 2002-12-20
US6297223B1 (en) 2001-10-02
UA42679C2 (uk) 2001-11-15
MC2307A1 (fr) 1993-09-27
GB9020930D0 (en) 1990-11-07
IL99562A (en) 1999-11-30
HU9300863D0 (en) 1993-06-28
SK23393A3 (en) 1993-07-07
ATE190489T1 (de) 2000-04-15
EP0550580B1 (en) 2000-03-15
CZ288520B6 (cs) 2001-07-11
NO980717D0 (no) 1998-02-20
MY128980A (en) 2007-03-30
US20070078106A1 (en) 2007-04-05
JPH1045623A (ja) 1998-02-17
EP0985415A1 (en) 2000-03-15
JPH06504263A (ja) 1994-05-19
KR100222329B1 (en) 1999-10-01
FI931337A (fi) 1993-03-25
US20020042392A1 (en) 2002-04-11
JP3003993B2 (ja) 2000-01-31
PT99041B (pt) 1999-02-26
PT99041A (pt) 1992-08-31
ES2143465T3 (es) 2000-05-16
HK1004188A1 (en) 1998-11-20
FI112601B (fi) 2003-12-31
SG47912A1 (en) 1998-04-17
FI931337A0 (fi) 1993-03-25
NO931118L (no) 1993-03-25
IL99562A0 (en) 1992-08-18
US6268374B1 (en) 2001-07-31
JP2682739B2 (ja) 1997-11-26
WO1992004901A1 (en) 1992-04-02
HUT63765A (en) 1993-10-28
NO313175B1 (no) 2002-08-26
CZ50693A3 (en) 1994-02-16
US7704971B2 (en) 2010-04-27
CZ288515B6 (cs) 2001-07-11
SK281894B6 (sk) 2001-09-11
DE69132052D1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
IL121947A0 (en) Pharmaceutical compositions containing uracil derivatives
HU912266D0 (en) Process for the production of solid medical preparations with controlled portioning of the active agents for oral use
AU7731691A (en) Prostaglandin analogues for use in medicine
GR3019508T3 (en) Derivatives of 2-aminopyrimidine-4-carboxamide, their preparation and therapeutic use
GB9010420D0 (en) New artist's easel
MY106314A (en) New tetrazole derivatives, process for their preparation and their use
GB8724371D0 (en) Artist's easel
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
AP9200355A0 (en) "Therapeutic agent"
SG49239A1 (en) Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
EP0347835A3 (en) Process for preparing aryl-ethyl phenols having one or more alkyl substituents in the ethyl group and their use
GR3019776T3 (en) Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof
MY111755A (en) Use of 4'-iodo-4'- deoxydoxorubicin for the treatment of amyloidosis.
ES8400747A1 (es) "procedimiento para la preparacion de 2-mesitilimino-3-alcohil-3,4,6,7-tetrahidro-2h-pirimido(6,1-a)isoquinolein-4-onas sustituidas en 9,10".
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
SI0711163T1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
GR3022441T3 (en) Use of interleukine 10 to produce drugs with a tumour-inhibiting action
HU912181D0 (en) Osmotic dosometer for use instead of infusion apparatus, for medical and other usage
MY103748A (en) A new antitumor agent obtained by microbial stereoselective reduction of 4-deoxy-4-iododoxorubicin